Showing 21-30 of 4174 results for "".
- Atopic Dermatitis Journal Club - Videoshttps://practicaldermatology.com/videos/practical-dermatology-journal-club-atopic-dermatitis/
- June 2024 - ISSUEShttps://practicaldermatology.com/issues/june-2024/
New Products/New in My Practice: Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-productsnew-in-my-practice-devices-2/23473/Social Distancing and Increased Sun Exposure: A Resource For Patients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/social-distancing-and-increased-sun-exposure-a-resource-for-patients/23391/As patients continue to favor outdoor events, it’s essential they protect their skin.Biosimilars: What's Coming for Labeling?
https://practicaldermatology.com/topics/practice-management/biosimilars-whats-coming-for-labeling/20934/The public comment period on draft labeling guidance will end next month.2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- ASLMS to Honor David J. Cuccia, PhDhttps://practicaldermatology.com/news/20120314-aslms_to_honor_david_j_cuccia_phd/2459844/David J. Cuccia, Ph.D, Chief Technology Officer and CEO at Modulated Imaging, Inc. Irvine, California, will receive the 2012 Dr. Horace Furumoto Innovations Professional Development Grant at the Annual Conference of the American Society for Laser Medicine and Surgery